| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
|
Lancet
|
2004
|
42.12
|
|
2
|
Apixaban versus warfarin in patients with atrial fibrillation.
|
N Engl J Med
|
2011
|
23.50
|
|
3
|
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.
|
Lancet
|
2008
|
13.15
|
|
4
|
Universal definition of myocardial infarction.
|
Circulation
|
2007
|
11.69
|
|
5
|
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.
|
Lancet
|
2010
|
11.25
|
|
6
|
Apixaban in patients with atrial fibrillation.
|
N Engl J Med
|
2011
|
9.97
|
|
7
|
Telmisartan to prevent recurrent stroke and cardiovascular events.
|
N Engl J Med
|
2008
|
7.25
|
|
8
|
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial.
|
JAMA
|
2005
|
6.68
|
|
9
|
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries.
|
JAMA
|
2007
|
6.38
|
|
10
|
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
|
Lancet
|
2010
|
6.31
|
|
11
|
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
|
N Engl J Med
|
2008
|
6.08
|
|
12
|
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data.
|
Lancet
|
2008
|
5.27
|
|
13
|
Apixaban with antiplatelet therapy after acute coronary syndrome.
|
N Engl J Med
|
2011
|
4.81
|
|
14
|
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
|
JAMA
|
2005
|
3.19
|
|
15
|
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.
|
JAMA
|
2007
|
3.09
|
|
16
|
Darapladib for preventing ischemic events in stable coronary heart disease.
|
N Engl J Med
|
2014
|
2.90
|
|
17
|
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
|
Circulation
|
2013
|
2.64
|
|
18
|
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
|
Stroke
|
2013
|
2.52
|
|
19
|
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.
|
Lancet Neurol
|
2008
|
2.07
|
|
20
|
Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction.
|
Circulation
|
2009
|
1.99
|
|
21
|
Tackling the challenge of cardiovascular disease burden in developing countries.
|
Am Heart J
|
2004
|
1.78
|
|
22
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
|
Circulation
|
2012
|
1.66
|
|
23
|
Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2.
|
Indian Heart J
|
2005
|
1.59
|
|
24
|
The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions.
|
Circulation
|
2010
|
1.51
|
|
25
|
Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction.
|
Am Heart J
|
2004
|
1.50
|
|
26
|
Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study.
|
J Am Coll Cardiol
|
2009
|
1.50
|
|
27
|
Correlation of regional cardiovascular disease mortality in India with lifestyle and nutritional factors.
|
Int J Cardiol
|
2005
|
1.40
|
|
28
|
Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry.
|
Circulation
|
2014
|
1.30
|
|
29
|
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
1.24
|
|
30
|
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
|
Am Heart J
|
2010
|
1.11
|
|
31
|
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
|
Eur Heart J
|
2013
|
1.03
|
|
32
|
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
|
Eur Heart J
|
2013
|
1.01
|
|
33
|
Perspectives on the management of coronary artery disease in India.
|
Heart
|
2007
|
0.99
|
|
34
|
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.
|
J Am Coll Cardiol
|
2011
|
0.94
|
|
35
|
Rationale and design of the Primary pREvention strategies at the community level to Promote Adherence of treatments to pREvent cardiovascular diseases trial number (CTRI/2012/09/002981).
|
Am Heart J
|
2013
|
0.93
|
|
36
|
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction.
|
Am Heart J
|
2009
|
0.85
|
|
37
|
Effect of fixed dose combinations of metoprolol and amlodipine in essential hypertension: MARS--a randomized controlled trial.
|
Blood Press Suppl
|
2011
|
0.81
|
|
38
|
Heart failure in India: an area of darkness.
|
Natl Med J India
|
2011
|
0.80
|
|
39
|
Clinical judgement & evidence-based medicine: time for reconciliation.
|
Indian J Med Res
|
2010
|
0.80
|
|
40
|
Polypharmacotherapy for primary prevention of cardiovascular disease.
|
Indian Heart J
|
2009
|
0.77
|
|
41
|
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
|
Nat Clin Pract Cardiovasc Med
|
2008
|
0.76
|
|
42
|
Physicians and their conscience.
|
Natl Med J India
|
2012
|
0.75
|
|
43
|
Preventing ischaemic heart disease in developing countries.
|
Evid Based Cardiovasc Med
|
2006
|
0.75
|
|
44
|
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.
|
Eur Heart J
|
2007
|
0.75
|
|
45
|
The Cochrane Library Oversight Committee.
|
Cochrane Database Syst Rev
|
2011
|
0.75
|